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Objective: The main objective of this study was to evaluate whether vaginal administration of 
probiotic Lactobacillus results in their colonization and persistence in the vagina and whether 
Lactobacillus colonization promotes normalization and maintenance of pH and Nugent score. 
Patients and methods: The study was a multicenter, randomized, double-blind, and placebo­
controlled trial. Altogether, 376 women were assessed for eligibility, and signed informed 
consent. One hundred and sixty eligible women with abnormal, also called intermediate, vaginal 
microflora, as indicated by a Nugent score of 4-6 and pH >4.5 and zero or low Lactobacillus 
count, were randomized. Each participant was examined four times during the study. Women 
were randomly allocated to receive either the probiotic preparation inVag®, or a placebo (one 
capsule for seven consecutive days vaginally). The product inVag includes the probiotic strains 
Lactobacillus fermentum 57A, Lactobacillus plantarum 57B, and Lactobacillus gasseri 57C. 
We took vaginal swabs during visits I, III, and IV to determine the presence and abundance of 
bacteria from the Lactobacillus genus, measure the pH, and estimate the Nugent score. Drug 
safety evaluation was based on analysis of the types and occurrence of adverse events. 
Results: Administration of inVag contributed to a significant decrease (between visits) in both 
vaginal pH (P<0.05) and Nugent score (P<0.05), and a significant increase in the abundance 
of Lactobacillus between visit I and visits III and IV (P<0.05). Molecular typing revealed the 
presence of Lactobacillus strains originating from inVag in 82% of women taking the drug at 
visit III, and 47.5% at visit IV. There was no serious adverse event related to inVag administra­
tion during the study.
Conclusion: The probiotic inVag is safe for administration to sustainably restore the healthy 
vaginal microbiota, as demonstrated by predominance of the Lactobacillus bacteria in vaginal 
microbiota.
Keywords: probiotics, Lactobacillus, bacterial vaginosis, aerobic vaginitis
Introduction
Vaginal microbiota is dominated by Gram-positive Lactobacillus bacteria, which 
maintain the acidic pH in the vagina and protect it from pathogen invasion by the produc­
tion of organic acid, bacteriocins, and hydrogen peroxide.1 Other bacterial species such 
as Gardnerella vaginalis, Peptostreptococcus spp., Prevotella spp., Escherichia coli, 
Streptococcus agalactiae, and Enterococcus faecalis are present in limited quantities 
in a healthy vagina, but in certain conditions, their populations may increase signifi­
cantly, which can cause diseases such as bacterial vaginosis (BV) or aerobic vaginitis 
(AV).2 These diseases are diagnosed using both clinical and microbiological criteria.
Dove ress 0  0  \ ©  2 0 15  Tom usiak et a l. Th is w o rk  is pub lished by Dove Medical P ress Lim ite d , and licensed under C reative Com m ons A ttribu tion  -  Non Com m ercia l (unp o rted , v 3 .0 )
http'//dxdoi org/10 2I47/DDDTS892I4 lic e n se . The full te rm s of the License a re  ava ilab le  a t http ://creativecom m o ns.o rg/ licenses/b y-nc/3 .0/,  Non-com m ercial uses o f the w o rk  a re  perm itted  w ith o u t any fu rth e r
perm ission fro m  Dove Medical Press Lim ite d , provided the w o rk  is p rop erly attribu te d . Perm issions beyond the scope of the license a re adm in iste red by Dove Medical Press Lim ite d , In fo rm ation on 
how to req uest perm ission m ay be found a t : h ttp ://w w w .dovepress.com /perm issions.php
submit your manuscript | www.dovepress.com D ru g  D e s ig n , D e v e lo p m e n t and T h e ra p y  2 0 1 5 :9  5 3 4 5 - 5 3 5 4  5345
Dru
g 
De
sig
n, 
De
ve
lop
m
en
t 
and
 
Th
era
py
 
do
wn
loa
de
d 
from
 
ht
tp
s:/
/w
ww
.d
ov
ep
re
ss
.co
m
/by
 
95
.17
4.4
5.1
45
 
on 
28
-M
ar
-2
02
0
Fo
r 
pe
rso
na
l 
use
 
on
ly.
T o m u s ia k  e t  al Dovepress
Clinical criteria include, among other signs and symptoms, 
elevated vaginal pH (> 4 .5 ),3 while the microbiological 
criterion involves the microscopic assessment of vaginal 
microbiota according to the Nugent score. A score of 4-6 
indicates an abnormal condition, also called intermediate 
vaginal microflora, and a score of 7-10 suggests the presence 
of BV.3,4 Abnormal vaginal microflora, although asymptom­
atic, often leads to vaginal infections when left untreated.4’5
Treating BV and AV with antibiotics and chemothera- 
peutics is often ineffective and results in relapses; however, 
administration of viable probiotic strains of Lactobacillus 
can promote success of these therapies, or they may be used 
as a prophylactic.6-8 As stated by Mastromarino et al9 the 
majority of clinical trials yielding positive results have been 
performed using probiotic preparations containing high doses 
of lactobacilli, suggesting that, beside strain characteristics, 
the amount of exogenously applied lactobacilli could have a 
role in the effectiveness of the product. However, substantial 
heterogeneity in products, trial methodologies, and outcome 
measures do not provide sufficient evidence for or against 
recommending probiotics for the treatment of BV. Therefore, 
each new probiotic product designed to improve vaginal health 
should be evaluated separately in controlled clinical studies.
Recently, Hemalatha et al10 published their study on 
vaginal tablets containing a probiotic mixture in which also 
women with symptomatic BV and with intermediate flora 
were involved. However, there is no published clinical trial 
specifically addressed to study the effects of probiotics on 
nonclinical parameters of the vaginal health in women with 
altered microbiota.
Objective
We aimed to evaluate whether vaginal administration of 
probiotic bacteria contained in a novel medicinal product 
consisting of three well-characterized Lactobacillus strains to 
women with abnormal microflora results in colonization and 
persistence of Lactobacillus in the vagina and a restoration 
of normal pH and reduction in the Nugent score as sensitive 
parameters of the vaginal healthy status. Further, we evalu­
ated drug safety by measuring the severity and frequency 
of adverse events following application of the probiotic 
preparation inVag®.
Patients and methods
study design
This m ulticenter, random ized, double-blind, placebo­
controlled, parallel-group study with two randomization 
arms (1:1) was conducted in accordance with the original
protocol PB-DM /SBR-L3 -  01/05. The trial received 
ethical approval on June 23, 2005, from the Independent 
Ethics Committee of Jagiellonian University (relevant for 
the study coordinator) and Regulatory Authority approval 
on September 21, 2005. This study has been entered into 
the Central Register of Clinical Trials under No 284/UR/ 
CEBK/09/05 dated September 27, 2005.
The study took place betw een February 2006 and 
June 2008 in nine study centers, the Gynecology Clinic 
University Hospital, and eight private outpatient gynecology 
practices (Krakow, Poland).
Participants and data collection
The trial involved 376 women (Figure 1); the first participant 
was enrolled in the trial on February 21, 2006, and the last 
participant completed the trial on June 13, 2008. The 160 
eligible participants consisted of 18-40-year-old women of 
European descent who needed to rebalance and/or restore 
their vaginal bacterial community, which was dysbiotic, ie, 
lacking of the Lactobacillus predominance, due to factors 
including antibiotic therapy, radiation therapy, chemo­
therapy, and hormonal therapy. Women who were qualified 
to the clinical trial did not manifest any clinical signs of 
acute inflammation of the genital tract, but only needed to 
rebalance and/or restore their vaginal bacterial microflora. 
The participants had suitable personal hygiene and provided 
written informed consent. Detailed inclusion and exclusion 
criteria can be found in Table 1.
The trial included four visits. The first visit included 
screening and enrollment; in the second visit the partici­
pants were randomized; and the third and fourth visits were 
follow-ups. Including the follow-up visits, the duration of 
participation in the trial was approximately 19 days. We 
allowed extension of the participation period by 7 days to 
account for interruptions in inVag administration due to 
menstruation.
A clinical investigator examined all participants and 
recorded medical histories and clinical symptoms. High 
vaginal swabs for wet preparations and Gram-stain smears 
were collected at visits I, III, and IV. Samples were sent 
to the central laboratory (Department of M icrobiology, 
Jagiellonian University Medical College, Krakow, Poland) 
for quantitative and qualitative analysis of microbiological 
cultures. These analyses included determination of the pres­
ence and abundance of Lactobacillus, bacterial and yeast 
pathogens, as well as vaginal pH and the Nugent score. The 
results from visits III and IV were compared with those 
from the first visit. Any adverse events following inVag
submit your manuscript | www.dovepress.com
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F igu re  1 Flowchart of the clinical study.
N ote : aAs per protocol, a participant could be withdrawn from the clinical trial for more than one reason.
administration were documented at visits III and IV based 
on medical history, physical examination, and analysis of 
“patient diary” entries.
The final inclusion criterion was based on the micro­
biological tests performed in the first visit. These results 
were confirmed by the second visit, and if the patient had a 
Nugent score of 4-6 , a low number or lack of Lactobacillus,
and/or a high vaginal pH, they were enrolled as participants, 
randomized, and allocated either inVag or the placebo 
according to a computer-generated sequence. The presence 
of the bacterial or fungal etiological agent of vaginal infec­
tion, whose number, based on viable count method, on the 
first visit was >1.0x105 colony forming units (CFU)/mL 
concurrent with the occurrence of clinical symptoms of
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Table 1 Patient exclusion and inclusion criteria
Inclusion criteria Exclusion criteria
Indications to rebalance and/or restore natural vaginal microbiota, due to antibiotic Patients <  18 years and > 45 years of age
therapy, radiation therapy, chemotherapy, hormonal therapy, etc Hypersensitivity to any of the ingredients contained in the
W om en aged >  18 years and < 45 years probiotic o r placebo
W om en of European descent Vaginal bleeding of unknown etiology
Suitable personal hygiene routines Positive result of a pregnancy test
suitable intellectual level that ensures appropriate cooperation Breastfeeding
Active genitourinary tract infection that requires antibiotic 
treatment against bacteria, viruses, fungi, o r protozoa 
Innate (congenital) and acquired immunodeficiencies 
Diabetes 
Mental illness
Status after bilateral adnexa removal 
Advanced cancer (terminal cancer)
Participation in another clinical study
vaginosis or vaginitis was the basis for exclusion from the 
study. Eligible women were given one package that con­
tained seven capsules. Starting from the day of the second 
visit, participants were to vaginally administer one capsule 
of probiotic or placebo daily before going to bed for seven 
consecutive days.
Randomization, allocation, and blinding
Each study center received randomization datasets and a 
set of packages containing the probiotic or placebo, labeled 
with numerical codes (from 001 to 280) assigned to one of 
the two treatment groups. Each participant was assigned an 
ID number composed of a two-digit study center number and 
a three-digit screening number. After randomization, a three­
digit randomization number (from 001 to 280) was added to 
the participant’s ID to identify the randomization dataset. The 
participants, investigators, clinic and central laboratory staff, 
and study monitors were blinded to the treatment group.
The tested product was a vaginal medicinal product in 
gelatin capsules (inVag) or a placebo. The manufacturer 
and sponsor (IBSS Biomed SA, Krakow, Poland) of the 
trial provided both the active product and placebo. The 
active product contained a mixture of three viable bacterial 
strains present at numbers > 1 0 9 CFU: 25% Lactobacillus 
fermentum  57A, 25% Lactobacillus plantarum  57B, 50% 
Lactobacillus gasseri 57C, and excipients. The placebo was 
identical in appearance but contained only excipients with 
no bacteria. Strains included in inVag are the lactic acid 
bacteria L. fermentum  57A, L. plantarum  57B, and L. gasseri 
57C, which were isolated from a vaginal swab taken from 
a healthy woman aged 27 years not using antibiotics for the 
last 3 months. The strains possessed high coaggregating 
abilities and naturally occurred as a triad strains complex.
Their species designation was confirmed by polymerse chain 
reaction for 16S RNA using species-specific primers, and 
they were identified using both pulse-field gel electrophoresis 
(L. ferm entum  57A and L. gasseri 57C) and multilocus 
sequence typing (L. plantarum  57B) methods to distinguish 
them from other strains in materials taken during clinical 
study. They have been deposited in the international collec­
tion of microorganisms and covered with a patent. They had 
been selected for commercial use on the basis of their high 
adherence ability to the A431 vaginal cell line (and also to 
Caco-2 enterocytes), ability of selected vaginal pathogen 
adhesion reduction already adhered to these lines, and 
broad antagonistic properties exerted against G. vaginalis, 
S. agalactiae, P. bivia, S. aureus, E. faecalis, C. difficile, 
and uropathogenic E. coli. L. gasseri 57C produces hydro­
gen peroxide. All of them are resistant to metronidazole and 
ciprofloxacin. L. fermentum  57A and L. plantarum  57B are 
vancomycin-resistant, while L. gasseri 57C is sensitive to 
vancomycin. The strains carry no extrachromosomal DNA 
elements able to transmit resistance to antibiotics, and they are 
resistant to spermicides such as nonoxynol-9 (and addition­
ally to gastric juice with pepsin pH 2.5 and to bile salts).
Microbiology
All tests were performed in a central laboratory. The material 
from the clinical samples was cultured in relevant growth 
media: MRS Agar (Oxoid) for Lactobacillus, Columbia 
Blood Agar (CBA, Difco) for aerobic bacteria, MacConkey 
Agar (Biocorp) for Gram-negative rods, Enterococcosel 
Agar (BBL) for E. faecalis, Schaedler Agar (Difco) with 
vitamin K and 5% sheep blood for anaerobic bacteria, and 
CBA with a suitable supplement of human blood for G. vagi­
nalis. For Candida fungi we used Sabouraud Agar (Biocorp).
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After cultivation in appropriate conditions, the pure cul­
tures were obtained and phenotypic characterization of the 
obtained isolates was made. We used the following API 
(bioMerieux) tests for species identification: API STREP (for 
Streptococcus and Enterococcus), API STAPH (for Staphy­
lococcus), API 20E (for Enterobacteriaceae), API 20A (for 
anaerobic bacteria), and API 50CH (for Lactobacillus). The 
results were analyzed with API LAB software for classifica­
tion of the test bacteria. The numbers of Lactobacillus and 
pathogens were measured by a standard viable count method 
on MRS Agar or other suitable agar as indicated earlier. 
Vaginal pH was determined using pH indicator strips by 
Merck (Germany) with a measuring range 4.0-7.0. Vaginal 
microflora was evaluated using a Gram-stained smear and 
the 10-point Nugent score.4 Additional analyses using poly- 
merse chain reaction11 for molecular species identification 
and pulse-field gel electrophoresis or multilocus sequence 
typing5,12 for intraspecific molecular typing were performed 
after the completion of the study to confirm colonization by 
the Lactobacillus strains contained in the active product.
safety evaluation
Our safety evaluation consisted of an assessment of the 
incidence and type of adverse events and serious adverse 
events after application of the tested product. Specifically, we 
analyzed the occurrence or intensification of local symptoms 
(pruritus, pain, vaginal discharge, labia swelling), allergic 
reaction, fever, hypogastric pain, pain during urination, 
breathing difficulties, and other unexpected adverse events. 
Data on adverse events were collected throughout the dura­
tion of patient participation in the study.
sample size
To calculate sample size, we assumed a test power of /> 0 .8 0 , 
a critical significance level P=0.05, and similar differences 
between treatment groups (active vs placebo) achieved in the 
preliminary study. This resulted in a suggested sample size 
equal to or greater than 56 participants. We assumed that 20% 
of participants might fail to complete the study per protocol, 
thus we recruited 68 women for each treatment group.
statistical analysis
The data were explained using descriptive statistical methods 
appropriate for the type of variables analyzed. For nominal 
variables, we determined the ratios of specific values. For 
continuous variables, we calculated the arithmetic mean (with 
standard error) and the median to define the central tenden­
cies. We also included data on variation such as standard
deviation, minimum and maximum values, and quartile 
limits. Due to the non-normal data distribution, for bacterial 
abundance measured in CFU/mL, a decimal-logarithmic data 
transformation was done. Inductive statistical methods were 
used to compare treatment groups. Because the distribution 
of quantitative variables significantly deviated from the 
normal distribution, even when data transformations were 
excluded, a nonparametric W ilcoxon rank-sum test was 
used. To avoid possible artifacts resulting from individual 
differences between patients, matched-pairs tests were used 
in comparisons between visits. For data analysis concerning 
the Nugent score, which is an ordinal variable, comparisons 
were made using a median test. For qualitative variables, 
Pearson’s x 2 (chi-square) tests or the less restrictive alterna­
tive G2 (likelihood ratio) tests were applied. If specific data 
were missing, pairwise deletion was used during the course 
of analysis.
Results
Baseline characteristics
Out of 376 women enrolled in the study, 160 were random­
ized, 112 completed the full study cycle, and 48 (30%) were 
excluded for various reasons (Figure 1). Efficacy evaluation 
was done for 112 women (61 received the active product 
and 51 received placebo) who completed the study as per 
protocol, ie, they completed all four visits and were not 
excluded (Table 2). Safety analysis was done for 141 women 
(76 received the active product and 65 received placebo) who 
were enrolled, randomized, and used at least one capsule of 
the product (Table 2).
Analysis of the data collected from patients during the 
first visit revealed that participant populations for efficacy 
and safety evaluations were not different in terms of demo­
graphic, clinical, or epidemiological parameters (Table 3).
Efficacy outcomes
The efficacy analysis based on 112 participants was based on 
vaginal pH, microbiological Nugent score, and degree and 
persistence of vaginal colonization by at least one of Lacto­
bacillus strains from the active product. Statistical analysis
Table 2 Populations of patients evaluated for safety and efficacy 
of inVag® treatment
Total number Patients Patients
of patients using inVag using placebo
Patients (randomized) 160 (100%) 86 (100%) 74 (100%)
safety evaluation (s) 141 (88%) 76 (88%) 65 (88%)
Efficacy evaluation (E) 112 (70%) 61 (71%) 51 (69%)
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Table 3 Baseline characteristics of participants
Characteristic Placebo inVag P-value
Average age of patients participating in the clinical study
Group Sa 31.12 29.14 0.1121
Group Eb 30.95 29.30 0.2468
Reason for visit 1 (enrollment to the study)
Follow-up after BV therapy (S) 21 20 0.4348
Follow-up after BV therapy (E) 16 16 0.5489
Follow-up after vaginal candidiasis treatment (S) 12 19 0.3501
Follow-up after vaginal candidiasis treatment (E) 7 16 0.1028
Follow-up after chemotherapy (S) 1 1 0.9113
Follow-up after chemotherapy (E) 1 1 0.8982
Follow-up after antibiotic treatmentc (S) 6 10 0.4636
Follow-up after antibiotic treatmentc (E) 3 8 0.2003
O ther (S) 34 45 0.4104
O ther (E) 27 36 0.5186
Number of BV o r vaginal candidiasis episodes
One (S) 8 11 0.3486 (S)
One (E) 6 8 0.2380 (E)
Tw o  (S) 3 6
Tw o  (E) 2 6
Three and more (S) 18 12
Three and more (E) 14 10
Use of an antibiotic/chemotherapeutic before enrollment to the clinical study
Oral 14 17 0.9307
Vaginal 15 17 0.2682
Intramuscular 0 1 0.2738
Intravenous 1 0 0.2009
Deviations from the norm observed by investigator at visit 1 during gynecological examination
Deviation from the norm (S) 5 10 0.2941
Deviation from the norm (E) 3 9 0.1306
Vaginal discharge (S) 3 1 0.2394
Vaginal discharge (E) 2 1 0.4563
Excessive secretion (S) 1 2 0.6539
Excessive secretion (E) 1 2 0.6671
Erythema (S) 0 1 0.2651
Erythema (E) 0 1 0.2688
Erosions of the epithelium (S) 1 1 0.9113
Erosions of the epithelium (E) 0 1 0.2688
Labia swelling (S) 0 1 0.2651
Labia swelling (E) 0 1 0.2688
O ther (S) 1 5 0.1394
O ther (E) 1 4 0.2408
O th er data in the medical h istory at visit 1
Sexual activity 44 51 0.6951
Use of condoms as a contraceptive method 7 16 0.0793
Use of vaginal douching 2 2 0.8554
Use of intimate hygiene products 24 32 0.5692
History of pregnancy 19 22 0.8965
History of undefined sexually transmitted diseases 3 3 0.8180
History of Chlamydia trachomatis infection 2 1 0.8270
Smoking 5 14 0.0649
Concom itant therapy
Concomitant therapy (S) 50 59 0.9202
Concomitant therapy (E) 37 46 0.7307
Hormone therapyd (S) 12 12 0.6739
Hormone therapyd (E) 10 10 0.6587
Contraception (S) 21 22 0.6657
Contraception (E) 16 17 0.6854
Menstrual cycle disorders (S) 6 11 0.3575
Menstrual cycle disorders (E) 5 9 0.4529
N otes: aSafety evaluation group; b Efficacy evaluation group; cfor reason other than BV and/or mycosis; dexcluding contraception. 
A b b rev ia tio n : BV, bacterial vaginosis.
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of the data revealed the following four main results: First, 
the group of women that received the probiotic experienced 
a significant reduction of vaginal pH between visits I and
III -  from 5.03 to 4.71 (P<0.0016) and between visits I and
IV -  from 5.03 to 4.66 (P<0.0001). A gradual decrease in 
vaginal pH was also seen in the placebo group; however, 
the change over time was not significant (Figure 2). Second, 
administration of the probiotic preparation resulted in a 
significant decrease in Nugent score between visit I and 
visits III -  from 2.12 to 1.25 (P=0.0001) and IV -  from 
2.12 to 0.9 (P<0.0001). Additionally, the Nugent score 
decreased significantly between visits III and IV from 1.25 
to 0.9 (P=0.0238), which occurred approximately 14 days 
after cessation of inVag treatment. This suggests that a 7-day 
treatment cycle with inVag results in significant improvement 
of the vaginal microflora. The Nugent score also decreased 
significantly between visit I and visits III (P<0.0001) and 
IV (P=0.0002), in women who received placebo, but this 
group did not show the continuous decrease between visits 
III and IV (Figure 3). Changes in the vaginal microflora 
in women who used the probiotic preparation (according 
to Nugent score) are shown in Figure 4. Third, women 
who used the active product had a significant increase of 
the abundance of L. plantarum  and L. fermentum  in their 
vaginal microbiota. These species increased approximately 
1,000 times over the 7 days (on average) after completion 
of the treatment (visit III), and then they slowly declined 
over the subsequent 8 days until visit IV. In patients who 
received the placebo, the abundance of L. plantarum  and 
L. fermentum  increased much more slowly than in patients 
who received the probiotic product. In this group, numbers of 
these strains only increased by ~10 times by the fourth visit.
The change in abundance of L. acidophilus and L. gasseri 
was similar in both treatment groups (Figure 5). Finally, the 
degree and sustainability of vaginal colonization by at least 
one Lactobacillus strain from the active product, based on 
molecular typing tests, confirmed colonization of the vaginal 
epithelium by L. fermentum  57A, L. plantarum  57B, and 
L. gasseri 57C in 82% of women who received the probiotic 
on visit III and 47.5% on visit IV.
safety outcomes
Safety analysis included 141 participants. Out o f the 
141 women, 133 completed the whole treatment, that is, 
used seven capsules of the probiotic or placebo. The rate of 
occurrence of adverse events was unrelated to assignment to 
either of the treatment groups (probiotic or placebo), as the 
number of adverse events in each group was similar. In the 
probiotic group, 79 women reported adverse events, and in 
the placebo group 67 women reported adverse events. A total 
of 146 adverse events were reported in both treatment groups, 
the most common being genitourinary tract events (60% of 
all reported adverse events); 88 adverse events of this type 
were reported in total.
A total of 49 genitourinary tract symptoms were observed 
in participants from the probiotic group. The most com­
mon symptoms reported by these women included vaginal 
discharge (16.46% of all symptoms observed in probiotic 
group), pruritus (12.66%), and hypogastric pain (7.59%).
A total of 67 adverse events were reported by 42 among 
65 participants receiving placebo. There were 39 cases of 
genitourinary system symptoms reported, dominated by 
vaginal discharge (19.40% of all symptoms in placebo group), 
pruritus (11.94%), and burning sensation (10.45%).
52_l
5.1 -  
5.0­
4.9-
4.6­
4.5­
4.4­
4.3-
V is itl Visit III Visit IV Visit I Visit III Visit IV
Patients receiving Patients receiving
inVag® placebo
F igu re  2 changes in vaginal pH in patients receiving inVag® or placebo at subsequent visits.
Drug Design, Development and Therapy 2015:9 submit your manuscript | ww^^epres«™ 5 3 5 1
Dovepress
Dru
g 
De
sig
n, 
De
ve
lop
m
en
t 
and
 
Th
era
py
 
do
wn
loa
de
d 
from
 
ht
tp
s:/
/w
ww
.do
ve
pr
es
s.c
om
/ 
by 
95
.17
4.4
5.1
45
 
on 
28
-M
ar
-2
02
0
Fo
r 
pe
rso
na
l u
se 
on
ly.
T o m u s ia k  e t  al Dovepress
z -  Wilcoxon test value P  -  significance level
Oo
CO
c
a)
O)3
2 . 0 -
1.5-
1 . 0 -
0.5-
V is itl Visit III Visit IV
Patients receiving 
inVag®
Visit I Visit III Visit IV
Patients receiving 
placebo
F igu re  3 changes in Nugent score in patients receiving inVag® or placebo at subsequent visits.
In both groups, a total of 71 adverse events were unre­
lated to the application of either probiotic or placebo, and 75 
adverse events were related to the application, but in most 
of these cases these were classified as “mild severity” and 
“unlikely related” . Analysis of the adverse events confirmed 
that no serious adverse event was related to the use of the 
probiotic.
Discussion
Safety and efficacy o f probiotic bacterial preparations have 
to be confirmed by results of well-controlled clinical studies. 
The clinical trial described here was a double-blind, placebo­
controlled clinical study, which demonstrated inVag therapy 
was significantly related to a gradual (visit-to-visit) decrease 
of vaginal pH and Nugent score. These positive changes 
likely resulted from colonization of the vaginal epithelium
by the bacteria contained in the probiotic preparation. Other 
randomized, double-blind clinical trials also confirmed a 
quick and significant decrease of pH and Nugent score in 
women using vaginal gynecological probiotics as compared 
to the respective placebo group.10,13 These results indicate 
that one key advantage of vaginally administered probiotics 
is their quick local action, which is driven by the activity of 
probiotic bacteria that adhere to and colonize the vaginal 
epithelium.
The probiotic bacteria (L. fermentum  57A, L. plantarum  
57B, and L. gasseri 57C) present in inVag were isolated 
from the healthy vaginal microbiota of a Polish woman. 
After the administration of inVag, we observed a fast and 
significant increase in the abundance of L. fermentum  57A, 
L. plantarum  57B, and L. gasseri 57C in the vaginal micro­
biota. These strains colonize vaginal environment rapidly
F igu re  4 Representative images of the improvement in vaginal vaginosis in one woman after vaginal application of inVag.
N otes: Gram-stained preparations evaluated under 1,000x magnification according to the 10-point Nugent scale. (A ) A  vaginal specimen obtained at visit i assessed at six points 
in nugent scale. (B ) a  vaginal specimen obtained on the third visit assessed at zero points in nugent scale.
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F igu re  5 comparison of changes in the abundance of L. fermentum, L. plantarum, 
and acidophilic Lactobacillus species in vaginal smears of patients receiving either 
inVag® or placebo.
A b b rev ia tio n s: cFU , colony forming units; L. fermentum, Lactobacillus fermentum; 
L. plantarum, Lactobacillus plantarum.
and have very strong antagonistic properties toward potential 
vaginal bacterial pathogens.5 Moreover, due to their ability to 
decrease the pH, these bacteria create favorable conditions for 
colonization by other Lactobacillus species that are regularly 
found in a healthy vaginal microbial community. Thus far, 
only two other clinical studies have reported the influence of 
probiotic strains with such well-characterized antagonistic 
and adhesive properties toward balancing vaginal bacterial 
microbiota.9,14 In one, Anukam et al investigated an oral 
preparation containing L. rhamnosus GR-1 and L. reuteri 
RC-14 strains, and in the second, Mastromarino et al studied 
vaginal tablets containing L. brevis CD2, L. salivarius FV2, 
and L. plantarum  FV9.9,14 Both studies demonstrated that 
administration of carefully selected Lactobacillus strains to 
women diagnosed with BV induces a faster restoration of 
healthy vaginal microbiota as compared to the control group 
and prevents remissions.
We used molecular typing to confirm the identity of 
Lactobacillus strains cultured from vaginal smears with 
those contained in inVag, which proved that the vaginal 
microbiota of 82% of women from the treatment group using 
inVag at visit III and 47.5% at visit IV were colonized with 
bacterial strains originating from inVag. Moreover, in 40% 
of patients, these bacteria were still present in vaginal smears 
after 15 days (on average) from the completion of treatment 
with inVag. These results demonstrate a stable colonization 
o f vaginal probiotic bacteria in women treated with inVag.
This study was designed to check only the effects of the 
probiotic drug on normalization o f the vaginal microbiota in 
women with altered/intermediate flora. Although initiation 
o f the positive changes in the microbiota is important for
this particular group of women, it is necessary to confirm 
whether InVag would be able to improve the clinical status 
in women with symptomatic BV and/or AV.
Probiotic preparations with viable lactic acid bacteria are 
generally regarded as safe because the bacteria are present 
in the healthy human vaginal microflora.15 Nevertheless, as 
with any biological preparation, adverse events o f varying 
intensity may occur related to its use. These adverse events 
may include allergic reactions related to a hypersensitivity 
to components in the probiotic.16,17 Our safety evaluations of 
inVag treatment revealed that adverse events were unrelated 
to the use o f the preparation or were reported as unlikely to 
be related and having mild severity. This analysis o f adverse 
events justifies treating the probiotic as safe.
In summary, vaginally administered inVag is a safe and 
efficient treatment to restore and/or rebalance the vaginal 
m icrobiota w ith characteristic predom inance o f lacto­
bacilli. Treatment with inVag also results in a reduction 
o f the vaginal pH and N ugent score, which indicates 
restoration of natural balance of the vaginal microbiota. 
We postulate that the use o f a gynecological probiotic 
is particularly recommended when quick restoration of 
vaginal m icrobiota is required, for example, after anti­
biotic treatment, chemotherapy, radiation therapy, or in 
supportive therapy o f vaginal inflammatory conditions. 
The use of oral probiotics, on the other hand, which not 
only protect the vagina but also the gastrointestinal tract, 
should be considered for recurrent and secondary bacte­
rial and fungal infections of the genitourinary system, in 
the peri- and postmenopausal period, and in women who 
frequently visit swimming pools, saunas, or Jacuzzis, and 
travel a lot.18 Indeed, the right choice o f the gynecologi­
cal probiotic is the first but crucial step to initiate rational 
approach to achieve healthy female genital m icrobiota 
in patients with abnormal microflora.
Conclusion
1) This study confirms the clinical and microbiological 
efficacy o f the drug inVag in rebalancing and/or restor­
ing the normal vaginal microbiota by providing probiotic 
bacteria that quickly and effectively colonize the vaginal 
epithelium.
2) The safety evaluation confirms that inVag is safe for use.
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